Skip to main content
Søg
Menu
Luk menu
Danmark
  • da
  • en
  • Sweden
  • Norway
  • Finland
  • Nordic
  • Global
  • da
  • en
Danmark
  • Sweden
  • Norway
  • Finland
  • Nordic
  • Global
  • Medarbejdere
  • Sektorer

    Detail

    Energi og forsyning

    Fast ejendom

    Finansiel sektor

    Forsikring

    Forsvar og sikkerhed

    Hotel, restauration og fritid

    Industri

    Landbrug og fødevarer

    Life Sciences

    Medier, sport og entertainment

    DLA_Ikon_Hospitality_and_Leisure-02

    Minedrift

    Shipping, transport og logistik

    Teknologi

  • Fagområder

    Fagområder

    Corporate M&A

    Ansættelsesret

    Energi og infrastruktur

    Finans

    IP og teknologi

    International handel, regulatoriske og offentlige forhold

    Insolvens og rekonstruktion

    Retssager, voldgift & undersøgelser

    Fast ejendom

    Skatteret

  • Karriere
  • Nyheder
  • Om os
  • DLA Piper Insights: ESG
  • Events
  • Podcasts
  • Webinarer
  • Videoer
  • Publikationer
  • Kontakt
Tilmeld dig vores nyhedsbreve
Aktuelt
Danish Life Science News January 2025

Danish Life Science News January 2025

Anette Moll Berg
Anette Moll Berg
Partner
Ulrik Bangsbo Hansen
Ulrik Bangsbo Hansen
Partner
Head of Life Sciences, Denmark
nyhed
31 jan 2025
Nyhedsbrev

DLA Piper’s experienced Life Science team presents an overview of notable Danish Life Science news from January 2025. In this article, you will find the following news.

  • New medicine types added to the list of critical medicines subject to the mandatory stock requirement 
  • EU moving closer to advances towards electronic package leaflets
  • Pharmaceutical companies to ensure labelling on medicine packages cannot be removed

New medicine types have been added to the list of critical medicines subject to the mandatory stock requirement 

The new Danish regulations concerning required pharmaceutical stock levels entered into force on June 1, 2024, and the requirement to maintain these stock levels became mandatory on January 1, 2025.The obligation applies to companies marketing any of the listed critical medicines in the Danish market. The obligation does not extend to parallel importers or distributors. However, marketing authorization holders, parallel distributors, and parallel importers are obliged to report their stock levels.

Consequently, companies marketing critical medicines in Denmark must build up a safety stock covering six weeks of the expected sales of the critical medicine by January 1, 2025. Additionally, they are required to report their stock levels of the critical medicine every two weeks. 

A new executive order updated the list of critical medicines to include 581 medicines now. This executive order does not come into force until January 1, 2025, which means that the stock to be built up by January 1, 2025, includes only the previously included 263 medicines. The newly added medicines must be reported starting April 1, 2025, and meet the mandatory stock requirement from July 1, 2025.

Companies may apply for full or partial exemption from the six-week stock requirement but not from the reporting obligation. 

Non-compliance with these obligations may result in fines and companies may incur criminal liability under the Danish Criminal Code.

EU moves closer to electronic package leaflets

European medicines agencies have been considering replacing hard-copy package leaflets in favor of electronic ones to reduce paper consumption and costs. In addition, the change would ensure that consumers always have access to the most up-to-date version of package leaflets. However, it may pose challenges for individuals lacking basic IT skills, IT equipment, or internet access.

In 2023-2024, Denmark participated in a pilot project with the Netherlands, Sweden, Spain, and the European Medicines Agency to test electronic package leaflets in a standardized format. The resulting report concluded that the EU is generally well prepared to phase in electronic package leaflets, but further IT development and integration are needed and will continue in 2025. The report recommends starting implementation alongside hard-copy package leaflets on a voluntary basis, with each country proceeding based on its IT readiness.

Denmark is participating in a Nordic pilot project that allows pharmaceutical companies to supply medicines to all Nordic countries with a hard-copy package leaflet in English and an electronic package leaflet in the respective national languages.

Pharmaceutical companies must ensure labelling on medicine packages cannot be removed

It is a requirement for labelling on medicine packages to be indelible. Among other things, it must not be possible for the expiration date and batch number to be erased. There are no standardized methods or guides on how to test this. The Danish Medicines Agency regularly tests that printed texts meet the requirement. The Danish Medicines Agency's laboratory published a description of how they check the indelibility of packaging on their website on January 7, 2025. They check it by holding at sample in their hands while covering the batch and expiration date for 20 seconds. Then they rub it 10 times. The test is documented with pictures and observations are noted down. In addition, the color of a print can also be tested through pantone color cards. Any color change will be visible here. In general, the label must be able to withstand being rubbed.

Download
Download som PDF
Fagområder
  • Life Sciences
Sektorer
  • Life Sciences
Share

Relevante nyheder

DLA Piper Global M&A Intelligence Report 2025
nyhed

Global M&A Intelligence Report 2025

23 maj 2025
Faglig nyhed
nyhed

Sø- og Handelsrettens Dom om Kæntring af Flydedok

14 maj 2025
Sager
Alle nyheder
Nyhedsbrev

Tilmeld dig vores nyhedsbreve

Kunne du tænke dig at modtage nyhedsbreve og invitationer til seminarer mm. inden for juridiske områder, der er relevante for dig? Så tilmeld dig et eller flere af vores nyhedsbreve her.
Tilmeld dig her

Hvad kan vi gøre for dig?

Jeg er ikke en robot Læs mere
To prevent bots, crawlers and similar malicious digital agents to spam and misuse webforms, a special checkbox like this can help to block such agents.
© 2025 DLA Piper

DLA Piper Denmark Advokatpartnerselskab

Oslo Plads 2
2100 København Ø
Danmark

DOKK1 Hack Kampmanns Plads 2, Niveau 3
8000 Aarhus C
Danmark

(+45) 33 34 00 00
denmark@dk.dlapiper.com

CVR nr.
35 20 93 52

  • Om os
  • Nyheder
  • Events
  • Podcasts
  • Webinarer
  • Videoer
  • Publikationer
  • Kontakt
  • DLA Piper Global
  • Alumni
  • Cookie politik
  • CSR
  • Legal notices
  • Forretningsbetingelser
  • Presse
  • Privatlivspolitik
  • Oplysningspligt
  • Betalingsoplysninger
  • Kreditorportal
  • Slavery and Human Trafficking Statement
Group 3 Created with Sketch. Group 2 Created with Sketch.
Tilmeld dig vores nyhedsbreve

DLA Piper er en global advokatvirksomhed, der driver virksomhed gennem en række særskilte juridiske enheder. For yderligere oplysninger om disse enheder og DLA Pipers struktur henvises til siden Legal Notices på vores globale hjemmeside. Med forbehold for alle rettigheder. Advokatannoncering.

Nej tak
Nyhedsbrev

Tilmeld dig vores nyhedsbreve

Kunne du tænke dig at modtage nyhedsbreve og invitationer til seminarer mm. inden for juridiske områder, der er relevante for dig? Så tilmeld dig et eller flere af vores nyhedsbreve her.
Tilmeld dig her